AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V., azienda farmaceutica europea specializzata in malattie rare, oggi ha annunciato l’espansione della sua presenza nel Regno Unito (UK) e la nomina di Sarah O’Connell a UK Country Manager. L’iniziativa rafforza l’impegno a lungo termine di Avanzanite in UK e la sua capacità di aiutare i pazienti idonei ad accedere a farmaci innovativi per malattie rare. “Il Regno Unito è essenziale per la nostra ambizione di sviluppare Avanzanite in un’aziend
Author: sHq_LoGiNz
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V., een Europees farmaceuticabedrijf dat zich op zeldzame ziekten richt, kondigde vandaag de uitbreiding van zijn aanwezigheid in de UK (United Kingdom) aan, alsook de benoeming van Sarah O’Connell tot UK Country Manager. Deze zet verstevigt de langetermijnverbintenis van Avanzanite met de UK en het vermogen van het bedrijf om hulp te bieden aan patiënten die in aanmerking komen om toegang te krijgen tot innovatieve geneesmiddelen voor zeldzam
ÁMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V., una empresa farmacéutica europea especializada en enfermedades raras, ha anunciado hoy la ampliación de su presencia en el Reino Unido y el nombramiento de Sarah O’Connell como directora nacional para el Reino Unido. Esta medida refuerza el compromiso a largo plazo de Avanzanite con el Reino Unido y su capacidad para ayudar a los pacientes que cumplan los requisitos a acceder a medicamentos innovadores para enfermedades raras. «El Reino Un
PORTLAND, Maine–(BUSINESS WIRE)– #ai–WEX® (NYSE: WEX), a global leader in intelligent payment solutions, and Euclid AI, the leading provider of agentic AI solutions for asset-based trucking, today announced an agreement to bring AI agents to WEX over-the-road (OTR) customers. Through the agreement, WEX and Euclid AI will work jointly to help WEX customers save time and money by embedding agentic AI at scale across their businesses. AI has become a business imperative for fleet operators. Carriers
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V., ein europäisches Pharmaunternehmen, das sich auf seltene Krankheiten spezialisiert hat, gab heute die Erweiterung seiner Präsenz im Vereinigten Königreich (UK) sowie die Ernennung von Sarah O’Connell zur Managerin für das Land bekannt. Dieser Schritt zeigt das langfristige Interesse des Unternehmens an dieser Region und ermöglicht betroffenen Patienten den Zugang zu innovativen Medikamenten für seltene Krankheiten. „Großbritannien ist für
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V., une société pharmaceutique européenne spécialisée dans les maladies rares, a annoncé aujourd’hui le renforcement de sa présence au Royaume-Uni et la nomination de Sarah O’Connell au poste de directrice nationale pour le Royaume-Uni. Cette décision renforce l’engagement à long terme d’Avanzanite envers le Royaume-Uni ainsi que sa capacité à aider les patients éligibles à accéder à des médicaments innovants destinés au traitement des maladie
LONDON–(BUSINESS WIRE)– #insurance–Security flaws in the PHP programming language, used by a majority of websites globally, highlights the potential of a systemic risk scenario and risk aggregation that has long-worried cyber insurers and resulted in a reluctance to increase their risk appetites aggressively, according to a new AM Best commentary.The recently discovered vulnerabilities within PHP could allow attackers to gain access to websites and steal sensitive information, as well as create backdoors
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 26.10.2026 FEUD IE00BF2FL590 335,317.00 EUR 18,423,760.99 54.944
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 26.10.2026 FEUZ IE00B8X9NY41 1,606,130.00 EUR 101,714,398.20 63.329